uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
3 reports, 2 independent
Updated Oct 13
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.An investigation is reported in New York City while uniQure develops its gene therapy.1 source
uniQure N.V. filed a BLA with the FDA for accelerated approval of its gene therapy.1 source
Keep exploring
The entities involved
Related events
- Clene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- A stock is reported to be traded on the Nasdaq exchange.
- INmune Bio Inc. listed its shares on the stock exchange on July 9, 2026.
- Eloxx Pharmaceuticals, Inc. began trading on the Nasdaq exchange on June 30, 2026.